111 related articles for article (PubMed ID: 3350834)
1. Cimetidine enhances cisplatin toxicity in mice.
Dorr RT; Soble MJ
J Cancer Res Clin Oncol; 1988; 114(1):1-2. PubMed ID: 3350834
[TBL] [Abstract][Full Text] [Related]
2. H2-antagonists and carmustine.
Dorr RT; Soble MJ
J Cancer Res Clin Oncol; 1989; 115(1):41-6. PubMed ID: 2564000
[TBL] [Abstract][Full Text] [Related]
3. Cimetidine enhancement of cyclophosphamide antitumour activity.
Dorr RT; Alberts DS
Br J Cancer; 1982 Jan; 45(1):35-43. PubMed ID: 7059463
[TBL] [Abstract][Full Text] [Related]
4. Interaction of cimetidine but not ranitidine with cyclophosphamide in mice.
Dorr RT; Soble MJ; Alberts DS
Cancer Res; 1986 Apr; 46(4 Pt 1):1795-9. PubMed ID: 3948164
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
6. The biological activity of cisplatin and dibromodulcitol in combination therapy.
Jeney A; Kovalszky I; Rásó E; Durand RE; Fürész J; Lapis K
Br J Cancer; 1995 Feb; 71(2):317-21. PubMed ID: 7841047
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Agata N; Mase T; Izumi H; Hirano S; Iguchi H; Tone H; Takeuchi T
Cancer Biochem Biophys; 1995 Nov; 15(2):95-101. PubMed ID: 8590441
[TBL] [Abstract][Full Text] [Related]
8. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.
Shirasaka T; Shimamoto Y; Ohshimo H; Saito H; Fukushima M
Cancer Chemother Pharmacol; 1993; 32(3):167-72. PubMed ID: 8500219
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
10. Attenuating the toxicity of cisplatin by using selenosulfate with reduced risk of selenium toxicity as compared with selenite.
Zhang J; Peng D; Lu H; Liu Q
Toxicol Appl Pharmacol; 2008 Feb; 226(3):251-9. PubMed ID: 17950769
[TBL] [Abstract][Full Text] [Related]
11. Interaction between cisplatin and mesna in mice.
Dorr RT; Lagel K
J Cancer Res Clin Oncol; 1989; 115(6):604-5. PubMed ID: 2514188
[TBL] [Abstract][Full Text] [Related]
12. Reduction of cisplatin toxicity and lethality by sodium malate in mice.
Ueda H; Sugiyama K; Yokota M; Matsuno K; Ezaki T
Biol Pharm Bull; 1998 Jan; 21(1):34-43. PubMed ID: 9477166
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.
Johnson CS; Chang MJ; Yu WD; Modzelewski RA; Grandis JR; Vlock DR; Furmanski P
Cancer Chemother Pharmacol; 1993; 32(5):339-46. PubMed ID: 8339383
[TBL] [Abstract][Full Text] [Related]
14. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
15. Enhanced therapeutic efficacy of cisplatin by combination with diethyldithiocarbamate and hyperthermia in a mouse model.
Murthy MS; Rao LN; Khandekar JD; Scanlon EF
Cancer Res; 1987 Feb; 47(3):774-9. PubMed ID: 3026616
[TBL] [Abstract][Full Text] [Related]
16. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
[TBL] [Abstract][Full Text] [Related]
17. Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle.
Aamdal S; Fodstad O; Kaalhus O; Pihl A
J Natl Cancer Inst; 1984 Sep; 73(3):743-52. PubMed ID: 6590919
[TBL] [Abstract][Full Text] [Related]
18. Drug interaction effects on antitumour drugs (X): exacerbation of cisplatin lethality by bacterial lipopolysaccharide in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Pharmacol Toxicol; 1991 May; 68(5):366-70. PubMed ID: 1946182
[TBL] [Abstract][Full Text] [Related]
19. [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
Uchida T; Nishikawa K; Shibasaki C; Okamoto K; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2275-82. PubMed ID: 2735770
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
